Review



pax7 rabbit polyclonal  (Aviva Systems)


Bioz Verified Symbol Aviva Systems is a verified supplier
Bioz Manufacturer Symbol Aviva Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91

    Structured Review

    Aviva Systems pax7 rabbit polyclonal
    Pax7 Rabbit Polyclonal, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 91/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/PAX7+Antibody+-+C-terminal+region+(ARP32742_P050)/pmc13752685-428-0-3
    Average 91 stars, based on 4 article reviews
    pax7 rabbit polyclonal - by Bioz Stars, 2026-11
    91/100 stars

    Images

    Related Articles

    other:

    Article Title: Fhl1 W122S causes loss of protein function and late-onset mild myopathy
    Article Snippet: Protein–antibody interaction was detected by peroxidase-conjugated mouse antibody, peroxidase-conjugated rabbit antibody or peroxidase-conjugated goat antibody using ECL Prime Western Blotting Detection Reagents (GE Healthcare, Buckinghamshire, UK).

    Article Title: Fhl1 W122S causes loss of protein function and late-onset mild myopathy.
    Article Snippet: Sections were imaged using an SP5 Leica confocal microscope (Leica Microsystems, Wetzlar, Germany).

    Incubation:

    Article Title: Cardiomyopathy and altered integrin-actin signaling in Fhl1 mutant female mice
    Article Snippet: .. The slides were subsequently incubated overnight at 4°C with rabbit polyclonal anti-FHL1 antibody, C-terminal region (1:100 dilution; ARP34378 T100, Aviva Systems Biology, San Diego, CA) and then with Alexa Fluor®-conjugated secondary antibody 488 goat anti-rabbit (1:1000 dilution; A11034, Molecular Probes by Life Technologies, Carlsbad, CA) at room temperature for 1 h, with DAPI for nuclear staining. .. Sections were imaged using an SP5 Leica confocal microscope (Leica Microsystems, Wetzlar, Germany).

    Article Title: Fhl1 W122S causes loss of protein function and late-onset mild myopathy
    Article Snippet: .. The slides were subsequently incubated overnight at 4°C with rabbit polyclonal anti-FHL1 antibody, C-terminal region ( {"type":"entrez-protein","attrs":{"text":"ARP34378","term_id":"1190165286","term_text":"ARP34378"}} ARP34378 T100, Aviva Systems Biology, San Diego, CA, USA, 1 : 100) and Mybpc1 (Developmental Studies Hybridoma Bank, ALD66, 0.6 μg/ml), and then with Alexa Fluor ® -conjugated secondary antibody 488 goat anti-rabbit and Alexa Fluor ® -conjugated secondary antibody 594 goat anti-mouse at room temperature for 1 h ( {"type":"entrez-nucleotide","attrs":{"text":"A11034","term_id":"489250","term_text":"A11034"}} A11034 and A11005, Molecular Probes by Life Technologies, Carlsbad, CA, USA, 1 : 1000), with or without DAPI for nuclear staining. .. Sections were imaged using an SP5 Leica confocal microscope (Leica Microsystems, Wetzlar, Germany).

    Staining:

    Article Title: Cardiomyopathy and altered integrin-actin signaling in Fhl1 mutant female mice
    Article Snippet: .. The slides were subsequently incubated overnight at 4°C with rabbit polyclonal anti-FHL1 antibody, C-terminal region (1:100 dilution; ARP34378 T100, Aviva Systems Biology, San Diego, CA) and then with Alexa Fluor®-conjugated secondary antibody 488 goat anti-rabbit (1:1000 dilution; A11034, Molecular Probes by Life Technologies, Carlsbad, CA) at room temperature for 1 h, with DAPI for nuclear staining. .. Sections were imaged using an SP5 Leica confocal microscope (Leica Microsystems, Wetzlar, Germany).

    Article Title: Fhl1 W122S causes loss of protein function and late-onset mild myopathy
    Article Snippet: .. The slides were subsequently incubated overnight at 4°C with rabbit polyclonal anti-FHL1 antibody, C-terminal region ( {"type":"entrez-protein","attrs":{"text":"ARP34378","term_id":"1190165286","term_text":"ARP34378"}} ARP34378 T100, Aviva Systems Biology, San Diego, CA, USA, 1 : 100) and Mybpc1 (Developmental Studies Hybridoma Bank, ALD66, 0.6 μg/ml), and then with Alexa Fluor ® -conjugated secondary antibody 488 goat anti-rabbit and Alexa Fluor ® -conjugated secondary antibody 594 goat anti-mouse at room temperature for 1 h ( {"type":"entrez-nucleotide","attrs":{"text":"A11034","term_id":"489250","term_text":"A11034"}} A11034 and A11005, Molecular Probes by Life Technologies, Carlsbad, CA, USA, 1 : 1000), with or without DAPI for nuclear staining. .. Sections were imaged using an SP5 Leica confocal microscope (Leica Microsystems, Wetzlar, Germany).



    Similar Products

    91
    Aviva Systems pax7 rabbit polyclonal
    Pax7 Rabbit Polyclonal, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/PAX7+Antibody+-+C-terminal+region+(ARP32742_P050)/pmc13752685-428-0-3
    Average 91 stars, based on 1 article reviews
    pax7 rabbit polyclonal - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    93
    Aviva Systems rabbit anti ank1
    Rabbit Anti Ank1, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/ANK1+antibody+-+C-terminal+region+(ARP42566_T100)/10__1038_slash_s41467___026___78907___w-480-27-29
    Average 93 stars, based on 1 article reviews
    rabbit anti ank1 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    ECM Biosciences signals for murf1
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    Signals For Murf1, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/MuRF1+(C-terminal+region)/pmc13534901-93-22-26
    Average 95 stars, based on 1 article reviews
    signals for murf1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    86
    Azenta c terminal p2 l2 s2 e1 e2 dyw region
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    C Terminal P2 L2 S2 E1 E2 Dyw Region, supplied by Azenta, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/dna+fragment/pm42045200-249-5-27
    Average 86 stars, based on 1 article reviews
    c terminal p2 l2 s2 e1 e2 dyw region - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    93
    ECM Biosciences anti arp2
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    Anti Arp2, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/Arp2+(C-terminal+region)/pmc13047250-48-4-13
    Average 93 stars, based on 1 article reviews
    anti arp2 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    ECM Biosciences anti arpc1b
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    Anti Arpc1b, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/Arpc1b%2Fp41-Arc+(C-terminal+region)/pmc13047250-48-9-13
    Average 93 stars, based on 1 article reviews
    anti arpc1b - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    ECM Biosciences anti arp3
    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, <t>MuRF1,</t> and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.
    Anti Arp3, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/Arp3+(C-terminal+region)/pmc13047250-48-6-13
    Average 93 stars, based on 1 article reviews
    anti arp3 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    ECM Biosciences atrogin 1
    a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function <t>of</t> <t>Atrogin-1</t> ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.
    Atrogin 1, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/MuRF1+(C-terminal+region)/bio_rxiv__64898__2026__02__27__708635-584-259-260
    Average 95 stars, based on 1 article reviews
    atrogin 1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    ECM Biosciences murf1
    a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function <t>of</t> <t>Atrogin-1</t> ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.
    Murf1, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/MuRF1+(C-terminal+region)/bio_rxiv__64898__2026__02__27__708635-584-254-255
    Average 95 stars, based on 1 article reviews
    murf1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    91
    Aviva Systems tdp 43
    a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function <t>of</t> <t>Atrogin-1</t> ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.
    Tdp 43, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/c+terminal+region/TARDBP+antibody+-+C-terminal+region+(ARP38942_T100)/pm41691309-427-68-71
    Average 91 stars, based on 1 article reviews
    tdp 43 - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    Image Search Results


    Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, MuRF1, and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.

    Journal: Biomolecules & Therapeutics

    Article Title: Maslinic Acid Alleviates Obesity-Associated Skeletal Muscle Atrophy and Adipose Tissue Dysfunction in Obese Mice

    doi: 10.4062/biomolther.2026.072

    Figure Lengend Snippet: Maslinic acid modulates atrophy-related marker expression in palmitic acid-treated C2C12 myotubes. Differentiated C2C12 myotubes were treated with MA (0-10 μM) and then challenged with PA (0.4 mM) under lipotoxic stress conditions. (A) Protein expression of myosin IIa, MuRF1, and Atrogin-1 was determined by Western blot analysis; GAPDH served as the internal control. (B-D) Immunofluorescence staining of (B) myosin IIa (green), (C) MuRF1 (green), and (D) Atrogin-1 (green) in differentiated C2C12 myotubes (200× original magnification); scale bar=50 μm. Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SEM from three independent experiments. * p <0.05, ** p <0.01 vs. the PA group.

    Article Snippet: The sections were incubated with primary antibodies (1:50) at 4°C overnight, followed by incubation with the corresponding secondary antibody for 1 h. Signals for MuRF1 (#MP3401; ECM Biosciences) and Atrogin-1 (ab168372; Abcam) were visualized using a DAB chromogenic substrate.

    Techniques: Marker, Expressing, Western Blot, Control, Immunofluorescence, Staining

    Maslinic acid modulates atrophy-related protein expression and GLUT4 expression in the skeletal muscle of obese mice. (A) Protein expression of pAKT, AKT, myosin IIa, MuRF1, and Atrogin-1 in gastrocnemius muscle was determined by Western blot analysis; GAPDH served as the internal control. (B) Immunofluorescence staining of GLUT4 (green) and (C) MuRF1 (green) in gastrocnemius muscle. (D) Immunohistochemical staining of MuRF1 (dark brown). (E) Immunofluorescence staining (red) and (F) immunohistochemical staining of Atrogin-1 (dark brown) in gastrocnemius muscle (100×original magnification); scale bar=50 μm. Nuclei in the immunofluorescence images were counterstained with DAPI (blue). Data are presented as mean ± SEM; n=12 per group. * p <0.05, ** p <0.01 vs. the HFD group.

    Journal: Biomolecules & Therapeutics

    Article Title: Maslinic Acid Alleviates Obesity-Associated Skeletal Muscle Atrophy and Adipose Tissue Dysfunction in Obese Mice

    doi: 10.4062/biomolther.2026.072

    Figure Lengend Snippet: Maslinic acid modulates atrophy-related protein expression and GLUT4 expression in the skeletal muscle of obese mice. (A) Protein expression of pAKT, AKT, myosin IIa, MuRF1, and Atrogin-1 in gastrocnemius muscle was determined by Western blot analysis; GAPDH served as the internal control. (B) Immunofluorescence staining of GLUT4 (green) and (C) MuRF1 (green) in gastrocnemius muscle. (D) Immunohistochemical staining of MuRF1 (dark brown). (E) Immunofluorescence staining (red) and (F) immunohistochemical staining of Atrogin-1 (dark brown) in gastrocnemius muscle (100×original magnification); scale bar=50 μm. Nuclei in the immunofluorescence images were counterstained with DAPI (blue). Data are presented as mean ± SEM; n=12 per group. * p <0.05, ** p <0.01 vs. the HFD group.

    Article Snippet: The sections were incubated with primary antibodies (1:50) at 4°C overnight, followed by incubation with the corresponding secondary antibody for 1 h. Signals for MuRF1 (#MP3401; ECM Biosciences) and Atrogin-1 (ab168372; Abcam) were visualized using a DAB chromogenic substrate.

    Techniques: Expressing, Western Blot, Control, Immunofluorescence, Staining, Immunohistochemical staining

    Proposed model summarizing the effects of maslinic acid on adipocyte metabolic dysfunction and skeletal muscle atrophic changes in obese mice. Maslinic acid (MA) reduced lipid accumulation and inflammation in adipose tissue, decreased M1 macrophage-associated marker expression, increased M2 macrophage-associated marker expression, and lowered TNF-α and IL-6 levels. In skeletal muscle and palmitic acid-treated C2C12 myotubes, MA increased AKT and FOXO1 phosphorylation and myosin IIa expression, while reducing MuRF1 and Atrogin-1 expression. MA was also associated with improved mitochondrial morphology and respiratory responses, increased mitofusin-2 expression, and reduced DRP1 phosphorylation. Collectively, these changes may contribute to the attenuation of obesity-associated skeletal muscle atrophic changes. Upward and downward arrows indicate increases and decreases, respectively.

    Journal: Biomolecules & Therapeutics

    Article Title: Maslinic Acid Alleviates Obesity-Associated Skeletal Muscle Atrophy and Adipose Tissue Dysfunction in Obese Mice

    doi: 10.4062/biomolther.2026.072

    Figure Lengend Snippet: Proposed model summarizing the effects of maslinic acid on adipocyte metabolic dysfunction and skeletal muscle atrophic changes in obese mice. Maslinic acid (MA) reduced lipid accumulation and inflammation in adipose tissue, decreased M1 macrophage-associated marker expression, increased M2 macrophage-associated marker expression, and lowered TNF-α and IL-6 levels. In skeletal muscle and palmitic acid-treated C2C12 myotubes, MA increased AKT and FOXO1 phosphorylation and myosin IIa expression, while reducing MuRF1 and Atrogin-1 expression. MA was also associated with improved mitochondrial morphology and respiratory responses, increased mitofusin-2 expression, and reduced DRP1 phosphorylation. Collectively, these changes may contribute to the attenuation of obesity-associated skeletal muscle atrophic changes. Upward and downward arrows indicate increases and decreases, respectively.

    Article Snippet: The sections were incubated with primary antibodies (1:50) at 4°C overnight, followed by incubation with the corresponding secondary antibody for 1 h. Signals for MuRF1 (#MP3401; ECM Biosciences) and Atrogin-1 (ab168372; Abcam) were visualized using a DAB chromogenic substrate.

    Techniques: Marker, Expressing, Phospho-proteomics

    a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function of Atrogin-1 ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.

    Journal: bioRxiv

    Article Title: Pancreatic cancer-associated organ dysfunction promotes muscle autophagy and contributes to peripheral tissue wasting

    doi: 10.64898/2026.02.27.708635

    Figure Lengend Snippet: a. Schematic showing experimental approach to disrupt autophagy in the muscle of mice with genetically engineered KP −/− F PDAC tumors. b. Western blot assessing Atg7 protein in muscle tissue from 6-week-old control ( Pdx-1-P2A-FlpO; Trp53 Frt/Frt ; Ckm-Cre ) or Atg7 muscle knock-out mice ( Ckm-Cre ; Atg7 fl/fl : referred to as Atg7 mKO), without or with ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt ) KP −/− F PDAC as indicated ( n = 3). Also shown is western blot for Atg7 in pancreas tissue from control and Atg7 mKO mice with KP −/− F PDAC ( n = 5). c. Western blot for Atg7, Atg5, p62, Lc3B-I, and Lc3B-II in gastrocnemius muscle from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC ( n = 2). Vinculin is blotted as a loading control. d. Gastrocnemius, quadriceps, and soleus skeletal muscle weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC). e. H&E staining of gastrocnemius muscle from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. f. Myofiber area quantification from histology shown in e. ( n = 230 control, n = 166 Atg7 mKO, n = 477 KP −/− F PDAC, and n = 186 Atg7 mKO KP −/− F PDAC from n = 4 mice for each group). g-l. Whole-body weight ( n = 14 control, n = 14 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 14 Atg7 mKO KP −/− F PDAC, 6-week-old) (g), food intake ( n = 5) (h), blood glucose ( n = 9) (i), plasma insulin ( n = 7 control, n = 6 Atg7 mKO, n = 5 PDAC, and n = 5 Atg7 mKO KP −/− F PDAC) (j), liver weight ( n = 11 control, n = 12 Atg7 mKO, n = 15 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (k), and perigonadal and subcutaneous ATs weights ( n = 14 control, n = 12 Atg7 mKO, n = 16 KP −/− F PDAC, and n = 11 Atg7 mKO KP −/− F PDAC) (l) normalized to whole-body weights of 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. m. H&E staining of perigonadal AT from control and Atg7 mKO mice with KP −/− F PDAC. n. Pancreas tissue weights normalized to whole-body weights from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated ( n = 11 control, n = 12 Atg7 mKO, n = 11 KP −/− F PDAC, and n = 12 Atg7 mKO KP −/− F PDAC). o. Gross images of pancreas from 6-week-old control and Atg7 mKO mice with KP −/− F PDAC as indicated ( n = 2). p. H&E staining of pancreas tissue from 6-week-old control or Atg7 mKO mice, without or with KP −/− F PDAC as indicated. q. Survival of control mice with KP −/− F PDAC ( Pdx-1-P2A-FlpO; Kras FSF-G12D/+ ; Trp53 Frt/Frt , referred to here as KP −/− F PDAC), or the same mice with a Ckm-Cre and one ( Atg7 fl/+ ) or two ( Atg7 fl/fl ) Atg7 fl alleles as indicated ( n = 43 PDAC, n = 50 Atg7 fl/+ , and n = 82 Atg7 fl/fl ). r. Survival of control or Atg7 mKO mice following orthotopic implantation of murine KPC PDAC cells into pancreas ( n = 6). s. Survival analysis of control mice and mice with muscle-specific loss of function of Atrogin-1 ( Atrogin-1 fl/fl ; Ckm-Cre: Atrogin-1 mLOF) following orthotopic pancreatic implantation of KPC PDAC cells ( n = 6). t. Survival analysis of control mice and mice with combined muscle-specific Atrogin-1 loss of function and Atg7 deletion ( Atrogin-1 mLOF; Atg7 mKO) following orthotopic KPC PDAC implantation ( n = 6). Both male and female mice were used in experiments. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test for data in panels c-j and m-n. P-values on survival experiments were calculated with Gehan-Breslow-Wilcoxon test. Data are presented as mean ± S.D., and n denotes the number of mice analyzed. Scale bars: 100 μm.

    Article Snippet: Membranes were blocked in 5% non-fat milk in TBS-T and probed overnight at 4 °C with the appropriate antibody diluted in 5% BSA in TBS-T. Primary antibodies were used including Vinculin (Cell Signaling Technology, 13901, clone E1E9V, 1:1,000), PRSS2 (Trypsin, Abclonal, A19275, 1:1,000), PNLIP (Pancreatic lipase, 11209-1AP-Proteintech, 1:1,000), Elastase (Abcam, ab21590, 1:1,000 dilution), α-Amylase (Santa Cruz, G10 clone-sc46657, 1:1,000), LC3B (Cell Signaling Technology, E7X4S, 1:1,000), phospho-ribosomal protein S6 Ser 235/236 (Cell Signaling Technology, 4858, 1/1,000), ribosomal protein S6 (Cell Signaling Technology, 2217, 1:1,000), phospho-p70 S6 kinase Thr389 (Cell Signaling Technology, 9205, 1:1,000), p70 S6 kinase (Cell Signaling Technology, 9202, 1:1,000), phospho-AMPK (Cell Signaling Technology, 2535, 1:1,000), AMPK (Cell Signaling Technology, 2532, 1:1,000), FOXO1 (Abclonal, A13862, 1:1,000), FOXO3A (Abclonal, A0102, 1:1,000), Anti-HA (Millipore-Sigma, 11867423001, 1:1,000), Cathepsin B (Cell Signaling Technology, D1C7Y, 1:1,000), Cathepsin L (R&D Systems, AF1515-SP, 1:1,000), ULK1 (Cell Signaling Technology, D8H5, 1:1,000), ATG5 (Cell Signaling Technology, D5F5U, 1:1,000), ATG7 (Sigma-Aldrich, A2856, 1:1,000), Puromycin (Sigma, MABE343, 1:10,000), EIF3F (Fortis Life Sciences, A303-005A-T, 1:1,000), Proteasome 20S Alpha7 subunit (ENZO Life sciences, BML-PW8110-0025, 1:1,000), Proteasome 19S Rpt3/S6b subunit (ENZO Life sciences, BML-PW8765-0025, 1:1,000), UBCJ2 (ENZO Life sciences, ENZ-ABS840-0100, 1:5,000), BNIP3 (Abcam, ab109362, 1:1,000), phosho-Acetyl-CoA Carboxylase I (S79) (Cell Signaling Technology, 6571S, 1:1,000), Acetyl-CoA Carboxylase I (Cell Signaling Technology, 3661S, 1:1,000), ATG3 (Cell Signaling Technology, 3415, 1:1,000), Calpain (Thermo Scientific, 9A4H8D3, 1:1,000), Lamp1 (Cell Signaling Technology, C54H11, 1:1,000), Lamp2 (Santa Cruz, H4B4, sc-18822, 1:1,000), Catalase (Cell Signaling Technology, D4P7B, 12980S, 1:1,000), Histone H3 (Cell Signaling Technology, D1H2, 4499T, 1:1,000), Cox IV (Cell Signaling Technology, 3E11, 4850T, 1:1,000), MuRF1 (ECM Biosciences, MP3401, 1:1,000), Atrogin-1 (ECM Biosciences, A2041P, 1:1,000).

    Techniques: Western Blot, Control, Knock-Out, Staining, Clinical Proteomics